Why advanced OA fails on one injection alone

For many patients with Kellgren-Lawrence Grade III or IV osteoarthritis, the conversation with a specialist reaches an uncomfortable middle ground: the joint is too worn for standard injectable therapies to make a meaningful difference, yet the patient is not ready — or not well enough — for joint replacement. This is sometimes called the 'impossible joint' problem, and it is more common than the neat rungs of the treatment ladder might suggest.

What makes this stage particularly difficult is that advanced OA is not a single-tissue failure. Two distinct structures deteriorate at once: the articular cartilage surface, which progressively loses its capacity to cushion and distribute load across the bone ends, and the synovial membrane, which in healthy joints secretes lubricating fluid and helps maintain the intra-articular environment. When both are compromised together, addressing only one leaves the other continuing to drive pain and structural decline.

Most single-agent injectables work within a narrow anatomical remit. Hyaluronic acid and corticosteroid primarily target the synovial fluid environment — they do not address cartilage structure. Platelet-rich plasma supports tissue healing but does not reconstitute a degraded synovial lining or scaffold the articular surface. None of these therapies was designed for a dual-compartment failure pattern at the advanced end of the OA spectrum.

A dual-injection approach targeting both compartments in a single session was developed specifically to fill this gap.

What each injection does inside the joint

Inside a grade III or IV knee, the joint has two anatomically distinct failure zones — and the CFI+ protocol assigns one injection to each.

At the deepest level sits the articular bone end, capped by what remains of the cartilage surface. This is where ChondroFiller injection (2.3 mL) is placed. The injectable collagen scaffold is delivered under ultrasound or fluoroscopic guidance directly to this surface, where it self-gels within minutes and forms a chemotactic matrix. Through a process called acellular matrix-induced chondrogenesis, progenitor cells migrate into the scaffold from the subchondral bone and surrounding synovium, differentiating into chondrocytes and producing new extracellular matrix. The scaffold itself then biodegrades as the repair tissue matures. ChondroFiller is the regenerative component of the protocol; its job is structural, working from the bony surface upward through the cartilage layer.

At the joint's inner lining — the synovial membrane — Arthrosamid (6 mL of 2.5% cross-linked polyacrylamide hydrogel, iPAAG) is injected into the synovial space. Rather than regenerating tissue, it integrates mechanically: synovial cells proliferate into the gel within 10–14 days, and a stable sub-synovial layer forms by day 30–90 that persists long-term. This cushions and reconstitutes the lining from the synovial interface inward. Arthrosamid is not a regenerative therapy and does not contribute to cartilage repair; describing both products as 'cartilage fillers' would misrepresent how they work.

The two mechanisms are anatomically complementary rather than overlapping. Neither product duplicates the other's role. Both are delivered in a single outpatient session — no general anaesthetic, no theatre — with the joint maintained in a fluid environment throughout to facilitate accurate image-guided placement.

The evidence behind each component

The clinical record for each component, taken separately, is moderately strong.

ChondroFiller

The knee evidence draws on a prospective randomised multicenter study of 23 patients, plus several independent series. Across these, IKDC scores improve by approximately 30 points at 12 months — clearing the established minimum clinically important difference of 16.7 points — with Jerosch et al.'s post-market follow-up recording a mean gain of 32.4 points sustained to three years and a final IKDC of 80. MOCART scores of 81.6–84.3 confirm structural repair with over 80% defect filling and good tissue integration. These outcomes come predominantly from focal cartilage defects in younger patients, a population meaningfully different from the advanced OA cohort that CFI+ targets.

The hip data introduce a direct caution. A prospective cohort of 26 patients (17 of 21 available at three-to-five-year follow-up) achieved good or excellent results when pre-existing OA was mild to absent (Tönnis grade 0–1), but outcomes were poor in Tönnis grade 2–3 joints. Applying ChondroFiller evidence to end-stage OA therefore requires extrapolation that the published literature does not fully bridge.

Arthrosamid

A systematic review of 463 patients confirmed statistically significant outcomes at 52 weeks and 13 months, with two-year durability and an adverse-event profile favourable to hyaluronic acid. A 150-patient retrospective cohort spanning KL grades II–IV found VAS scores drop from 7 to 3 at three months; at six months, iPAAG still outperformed corticosteroid (p<0.001), while both HA and steroid had returned to baseline by 12 months. Histopathological studies in equine and rabbit models confirm that the sub-synovial gel layer persists at two years, and transcriptomic analysis of iPAAG-treated equine synovium identifies downregulation of TNF-α and T-cell signalling pathways at day 28 — suggesting the sustained pain relief reflects immune modulation, not mechanical cushioning alone.

The combination evidence gap

No published RCT or controlled trial has tested CFI+ as a combined protocol. The rationale for pairing the two injections rests on component-level evidence and anatomical complementarity, not on a dedicated combination study. That gap should be named plainly: CFI+ is a biologically coherent dual-compartment strategy, but prospective combination data do not yet exist.

Which patients are suited to CFI+

CFI+ was designed for a specific and narrow population, not for everyone with knee pain or early joint wear.

The protocol is most likely to be considered if:

• Your imaging confirms Kellgren-Lawrence Grade III or IV osteoarthritis — joint space narrowing, osteophytes, and significant cartilage loss, not mild wear.
• Both compartments are affected: the articular surface is damaged and the synovial lining is involved. If imaging and examination suggest an otherwise healthy synovium, ChondroFiller injection alone may address the problem without the need for a combined approach.
• You have already tried simpler injectables — hyaluronic acid, corticosteroid, or equivalent — without lasting benefit. CFI+ sits above that tier; patients still in the HA or steroid phase are not the intended group.
• Joint replacement is not yet appropriate or is something you are actively trying to defer.

Where the evidence has limits

ChondroFiller's clinical record is strongest in focal, contained defects rather than the diffuse joint-surface damage typical of end-stage OA. Applying that data to KL Grade III/IV joints requires extrapolation, and the published literature does not fully bridge that gap — a distinction any patient considering CFI+ should understand.

For the hip specifically, the available cohort data show a clear severity threshold: good outcomes were recorded at Tönnis grade 0–1, but poor results emerged at Tönnis grade 2–3. Given that CFI+ targets an advanced-OA population, this is a genuine limitation rather than a minor footnote, and it should form part of any pre-treatment discussion.

Suitability ultimately depends on imaging findings, symptom pattern, and prior treatment history — factors that vary considerably between individuals. A specialist assessment is the right starting point for anyone considering this protocol.

The outpatient session and what recovery involves

Recovery begins the moment the session ends — and understanding why the post-injection period is structured as it is makes it easier to follow.

The loading restriction after CFI+ is not precautionary in the routine sense. In vitro friction testing confirmed that ChondroFiller, during its early integration phase, cannot reduce damage to opposing cartilage surfaces under cyclic loading — the scaffold is mechanically unstable until stable defect filling is achieved. Returning to full weight-bearing before that point risks disrupting the collagen matrix before the patient's own progenitor cells have had time to migrate in, differentiate, and begin consolidating the repair. The restriction is a biological requirement of the scaffold's integration sequence, not a generic post-injection caution applied to all joint injections.

Arthrosamid's synovial effect also matures progressively — as the histopathological integration sequence covered in the evidence section establishes. Both products therefore require weeks to consolidate, and the two timelines run in parallel rather than sequentially.

As a rough order of magnitude, graduated loading typically begins several weeks after the session, with a return to more demanding activity subject to clinical review. Specific milestones depend on imaging findings, the joint involved, and individual response — these are confirmed at follow-up rather than fixed in advance. Patients should expect a period of reduced load, plan accordingly, and treat any temptation to accelerate that phase as a risk to the scaffold's integration, not simply an inconvenience.

Realistic expectations and where to find out more

Two signals warrant naming before any decision is made.

ChondroFiller's early integration window — the biomechanical instability period described in the context of loading restrictions — is the scaffold's most vulnerable phase. Post-injection guidance exists for a clinical reason, not as a routine precaution applied to all joint injections.

The iPAAG signal concerns long-term monitoring. Arthrosamid's synovial integration is characterised, in the histopathological literature itself, as a macrophage-driven foreign body response — one that stabilises into a durable sub-synovial layer within 30 to 90 days in animal models. A single foreign body granuloma was reported in 2014 following intra-articular polyacrylamide injection; that case pre-dates the current 2.5% formulation, and subsequent in vitro testing found no neurotoxicity at concentrations up to 20%. Because iPAAG is permanent in the joint, long-term follow-up is appropriate rather than optional.

On the evidence: component-level data across both products covers hundreds of patients, and the dual-compartment biological rationale is coherent. A published trial testing the combination directly does not yet exist, and patients weighing this decision should factor that in alongside everything else.

What CFI+ can reasonably offer is pain reduction and structural support across both joint compartments — for patients who have exhausted single-injection options and are trying to delay or avoid replacement. It is not a reversal of end-stage OA, and should not be approached as one.

Individual suitability depends on imaging findings, OA grade, the joint involved, and treatment history. Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street; information and appointments are at londoncartilage.com. Whether CFI+ is the right step for a specific patient only becomes answerable face-to-face, with imaging in hand.

1. [1] A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. (2022). https://doi.org/10.18103/mra.v10i8.2950 https://doi.org/10.18103/mra.v10i8.2950
2. [2] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
4. [4] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Controlled Randomized Multicenter Study: ChondroFiller liquid vs Microfracturing for Focal Cartilage Defects of the Knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
6. [6] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
7. [7] Intra-articular 2.5% polyacrylamide hydrogel alters synovial immune pathways in equine experimental osteoarthritis. (2026). https://doi.org/10.2460/ajvr.26.04.0181 https://doi.org/10.2460/ajvr.26.04.0181